31 research outputs found
Towards Real-World Test-Time Adaptation: Tri-Net Self-Training with Balanced Normalization
Test-Time Adaptation aims to adapt source domain model to testing data at
inference stage with success demonstrated in adapting to unseen corruptions.
However, these attempts may fail under more challenging real-world scenarios.
Existing works mainly consider real-world test-time adaptation under non-i.i.d.
data stream and continual domain shift. In this work, we first complement the
existing real-world TTA protocol with a globally class imbalanced testing set.
We demonstrate that combining all settings together poses new challenges to
existing methods. We argue the failure of state-of-the-art methods is first
caused by indiscriminately adapting normalization layers to imbalanced testing
data. To remedy this shortcoming, we propose a balanced batchnorm layer to swap
out the regular batchnorm at inference stage. The new batchnorm layer is
capable of adapting without biasing towards majority classes. We are further
inspired by the success of self-training~(ST) in learning from unlabeled data
and adapt ST for test-time adaptation. However, ST alone is prone to over
adaption which is responsible for the poor performance under continual domain
shift. Hence, we propose to improve self-training under continual domain shift
by regularizing model updates with an anchored loss. The final TTA model,
termed as TRIBE, is built upon a tri-net architecture with balanced batchnorm
layers. We evaluate TRIBE on four datasets representing real-world TTA
settings. TRIBE consistently achieves the state-of-the-art performance across
multiple evaluation protocols. The code is available at
\url{https://github.com/Gorilla-Lab-SCUT/TRIBE}.Comment: 23 pages, 7 figures and 22 table
Sirtuin 1 and Autophagy Attenuate Cisplatin-Induced Hair Cell Death in the Mouse Cochlea and Zebrafish Lateral Line
Cisplatin-induced ototoxicity is one of the major adverse effects in cisplatin chemotherapy, and hearing protective approaches are unavailable in clinical practice. Recent work unveiled a critical role of autophagy in cell survival in various types of hearing loss. Since the excessive activation of autophagy can contribute to apoptotic cell death, whether the activation of autophagy increases or decreases the rate of cell death in CDDP ototoxicity is still being debated. In this study, we showed that CDDP induced activation of autophagy in the auditory cell HEI-OC1 at the early stage. We then used rapamycin, an autophagy activator, to increase the autophagy activity, and found that the cell death significantly decreased after CDDP injury. In contrast, treatment with the autophagy inhibitor 3-methyladenine (3-MA) significantly increased cell death. In accordance with in vitro results, rapamycin alleviated CDDP-induced death of hair cells in zebrafish lateral line and cochlear hair cells in mice. Notably, we found that CDDP-induced increase of Sirtuin 1 (SIRT1) in the HEI-OC1 cells modulated the autophagy function. The specific SIRT1 activator SRT1720 could successfully protect against CDDP-induced cell loss in HEI-OC1 cells, zebrafish lateral line, and mice cochlea. These findings suggest that SIRT1 and autophagy activation can be suggested as potential therapeutic strategies for the treatment of CDDP-induced ototoxicity
A novel pore-region mutation, c.887G > A (p.G296D) in KCNQ4, causing hearing loss in a Chinese family with autosomal dominant non-syndromic deafness 2
Overexpression of BID in thyroids of transgenic mice increases sensitivity to iodine-induced autoimmune thyroiditis
Abstract
Background
BID functions as a bridge molecule between death-receptor and mitochondrial related apoptotic pathways to amplify apoptotic signaling. Our previous studies have demonstrated a substantial increase in BID expression in primary normal thyroid epithelia cells treated with inflammatory cytokines, including the combination of IFNγ and IL-1β or IFNγ and TNFα. The aim of this study was to determine whether an increase in BID expression in thyroid can induce autoimmune thyroiditis.
Methods
A transgenic mouse line that expresses human BID in thyroid cells was established by fusing a mouse thyroglobulin (Tg) promoter upstream of human BID (Tg-BID). We tested whether the increased expression of pro-apoptotic BID in thyroid would induce autoimmune thyroiditis, both in the presence and absence of 0.3% iodine water.
Results
Our data show that Tg-BID mice in a CBA/J (H-2Â k) background do not spontaneously develop autoimmune thyroiditis for over a year. However, upon ingestion of iodine in the drinking water, autoimmune thyroiditis does develop in Tg-BID transgenic mice, as shown by a significant increase in anti-Tg antibody and mononuclear cell infiltration in the thyroid glands in 30% of mice tested. Serum T4 levels, however, were similar between iodine-treated Tg-BID transgenic mice and the wild type mice.
Conclusions
Our data demonstrate that increased thyroid expression of BID facilitates the development of autoimmune thyroiditis induced by iodine uptake. However, the overexpression of BID itself is not sufficient to initiate thyroiditis in CBA/J (H-2Â k) mice.http://deepblue.lib.umich.edu/bitstream/2027.42/109466/1/12967_2014_Article_1889.pd
A Supply Chain-Logistics Super-Network Equilibrium Model for Urban Logistics Facility Network Optimization
The logistics facility decisions may be the most critical and most difficult of the decisions needed to realize an efficient supply chain since these decisions have significant effects on the logistics costs generated in the logistics network. We establish a logistics super network equilibrium integrating urban logistics facilities with members of traditional supply chain network, using the variational inequality theory. This model takes into account the behavior of logistics facilities and the transactions between retailers and logistics facilities are examined in this paper. Furthermore, we obtain the equilibrium condition of the system, and the economic explanation and algorithm are given. Finally, some verification examples are provided to verify the solution and decision-making application
A Supply Chain-Logistics Super-Network Equilibrium Model for Urban Logistics Facility Network Optimization
Modified Nanoemulsions with Iron Oxide for Magnetic Resonance Imaging
A nanoemulsion (NE) is a surfactant-based, oil-in-water, nanoscale, high-energy emulsion with a mean droplet diameter of 400–600 nm. When mixed with antigen and applied nasally, a NE acts as a mucosal adjuvant and induces mucosal immune responses. One possible mechanism for the adjuvant effect of this material is that it augments antigen uptake and distribution to lymphoid tissues, where the immune response is generated. Biocompatible iron oxide nanoparticles have been used as a unique imaging approach to study the dynamics of cells or molecular migration. To study the uptake of NEs and track them in vivo, iron oxide nanoparticles were synthesized and dispersed in soybean oil to make iron oxide-modified NEs. Our results show that iron oxide nanoparticles can be stabilized in the oil phase of the nanoemulsion at a concentration of 30 µg/μL and the iron oxide-modified NEs have a mean diameter of 521 nm. In vitro experiments demonstrated that iron oxide-modified NEs can affect uptake by TC-1 cells (a murine epithelial cell line) and reduce the intensity of magnetic resonance (MR) images by shortening the T2 time. Most importantly, in vivo studies demonstrated that iron oxide-modified NE could be detected in mouse nasal septum by both transmission electron microscopy and MR imaging. Altogether these experiments demonstrate that iron oxide-modified NE is a unique tool that can be used to study uptake and distribution of NEs after nasal application
Induction of immune tolerance in mice with a novel mucosal nanoemulsion adjuvant and self-antigen
Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report
Background Collecting duct carcinoma (CDC) of the kidney is a rare and highly aggressive malignant tumor with the worst prognosis among all renal cancers. Nevertheless, the first-line treatments, including chemotherapy and target therapy, usually show poor response to CDC. Recent studies have suggested that immunotherapy targeting personal tumor-specific neoantigens could be a promising strategy for several solid cancers. However, whether it has therapeutic potential in CDC remains unclear.Case presentation Here, we report a case of an Asian patient who underwent personalized neoantigen-based immunotherapy. The patient was diagnosed with metastatic CDC and suffered extensive tumor progression following sorafenib treatment. Based on the patient’s own somatic mutational profile, a total of 13 neoantigens were identified and corresponding long-peptide vaccine and neoantigen-reactive T cells (NRTs) were prepared. After six cycles of neoantigen-based vaccination and T-cell immunotherapy, the patient was reported with stable disease status in tumor burden and significant alleviation of bone pain. Ex vivo interferon-γ enzyme-linked immunospot assay proved the reactivity to 12 of 13 neoantigens in peripheral blood mononuclear cells collected after immunotherapy, and the preferential reactivity to mutant peptides compared with corresponding wild-type peptides was also observed for 3 of the neoantigens. Surprisingly, biopsy sample collected from CDC sites after 3 months of immunotherapy showed decreased mutant allele frequency corresponding to 92% (12/13) of the neoantigens, indicating the elimination of tumor cells carrying these neoantigens.Conclusions Our case report demonstrated that the combined therapy of neoantigen peptide vaccination and NRT cell infusion showed certain efficacy in this CDC case, even when the patient carried only a relatively low tumor mutation burden. These results indicated that the personalized neoantigen-based immunotherapy was a promising new strategy for advanced CDC.Trial registration number ChiCTR1800017836